Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis

Clinical Immunology Communications Pub Date : 2022-12-01 DOI:10.1016/j.clicom.2022.01.002

Giuseppe A. Ramirez , Adriana Cariddi , Silvia Noviello , Corrado Campochiaro , Valentina Canti , Luca Moroni , Mona-Rita Yacoub , Elena M. Baldissera , Enrica P. Bozzolo , Lorenzo Dagna

{"title":"Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis","authors":"Giuseppe A. Ramirez , Adriana Cariddi , Silvia Noviello , Corrado Campochiaro , Valentina Canti , Luca Moroni , Mona-Rita Yacoub , Elena M. Baldissera , Enrica P. Bozzolo , Lorenzo Dagna","doi":"10.1016/j.clicom.2022.01.002","DOIUrl":null,"url":null,"abstract":"<div>Little is known about the efficacy and safety of the anti-interleukin 5 monoclonal antibody mepolizumab (MPZ) in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in real-life. We thus evaluated disease activity, damage and disease-related complications in 14 patients with EGPA receiving MPZ for refractory disease for a median time of 16 months in comparison with up to five years before MPZ start. Asthma exacerbation rates, the Birmingham Vasculitis Activity Score and corticosteroid dosage decreased during MPZ (p < 0.001, p < 0.001 and p = 0.001, respectively). Five patients could discontinue prednisone. Infection rates were higher during MPZ (p < 10–6), but no rises in hospitalizations, asthma exacerbations or damage accrual were observed. Real-life data confirm the effectiveness of MPZ in refractory EGPA with active asthma. Higher infections rates are in line with other studies and might be due to relative overreporting secondary to increased visit frequency, although a pharmacological effect could not be ruled out.</div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000026/pdfft?md5=75f1aaeb7ec37ac86b981dbe92716b4d&pid=1-s2.0-S2772613422000026-main.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772613422000026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Little is known about the efficacy and safety of the anti-interleukin 5 monoclonal antibody mepolizumab (MPZ) in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in real-life. We thus evaluated disease activity, damage and disease-related complications in 14 patients with EGPA receiving MPZ for refractory disease for a median time of 16 months in comparison with up to five years before MPZ start. Asthma exacerbation rates, the Birmingham Vasculitis Activity Score and corticosteroid dosage decreased during MPZ (p < 0.001, p < 0.001 and p = 0.001, respectively). Five patients could discontinue prednisone. Infection rates were higher during MPZ (p < 10^–6), but no rises in hospitalizations, asthma exacerbations or damage accrual were observed. Real-life data confirm the effectiveness of MPZ in refractory EGPA with active asthma. Higher infections rates are in line with other studies and might be due to relative overreporting secondary to increased visit frequency, although a pharmacological effect could not be ruled out.

查看原文本刊更多论文

mepolizumab治疗嗜酸性肉芽肿合并多血管炎的临床疗效和安全性

抗白细胞介素5单克隆抗体mepolizumab (MPZ)在现实生活中对嗜酸性肉芽肿病合并多血管炎(EGPA)患者的疗效和安全性知之甚少。因此，我们评估了14例接受MPZ治疗难治性疾病的EGPA患者的疾病活动性、损伤和疾病相关并发症，中位时间为16个月，而MPZ治疗前最长为5年。MPZ期间哮喘加重率、伯明翰血管炎活动度评分和皮质类固醇剂量下降(p <0.001, p <0.001和p = 0.001)。5例患者可以停用强的松。MPZ期间感染率较高(p <10-6)，但没有观察到住院、哮喘加重或损伤增加。实际数据证实了MPZ治疗难治性EGPA伴活动性哮喘的有效性。较高的感染率与其他研究一致，可能是由于就诊频率增加导致的相对多报，尽管不能排除药理学作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Immunology Communications

自引率

0.00%

发文量